<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(21)</volume><submitter>Wang J</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>The role of Vitamin D (VD) in calcium balance and bone health makes VD a vital factor in osteoarthritis (OA). Studies that have evaluated the effect of VD on OA patients have mainly been performed on a short-term basis. In this analysis, we aimed to evaluate whether VD was associated with mortality, a long-term outcome, in OA patients.&lt;h4>Methods&lt;/h4>Participants with self-reported OA from NHANES III and NHANES 2001-2018 were included. Associations of 25(OH)D concentrations with mortality risk were assessed continuously using restricted cubic splines and by categories (i.e., &amp;lt;25.0, 25.0-49.9, 50.0-74.9, and ≥75.0 nmol/L) using the Cox regression model. Sensitivity and stratified analyses were performed to evaluate the robustness of the results.&lt;h4>Results&lt;/h4>A total of 4570 patients were included, of which 1388 died by 31 December 2019. An L-shaped association was observed between 25(OH)D concentrations and all-cause mortality, whereas an inverse association was found for cardiovascular disease (CVD) mortality. The adjusted hazard ratios (95% confidence intervals) across four categories were 1.00 (reference), 0.49 (0.31, 0.75), 0.45 (0.29, 0.68), and 0.43 (0.27, 0.69) for all-cause mortality and 1.00 (reference), 0.28 (0.14, 0.59), 0.25 (0.12, 0.51), and 0.24 (0.11, 0.49) for CVD-specific mortality; no significant associations were found for cancer-specific mortality. Similar results were observed when stratified and sensitivity analyses were performed.&lt;h4>Conclusions&lt;/h4>Compared with patients with insufficient or deficient serum 25(OH)D, those with sufficient 25(OH)D concentrations had a lower risk of all-cause and CVD mortality, supporting a beneficial role of VD on a long-term basis.</pubmed_abstract><journal>Nutrients</journal><pagination>4629</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9655488</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in Osteoarthritis Patients: Results from NHANES III and NHANES 2001-2018.</pubmed_title><pmcid>PMC9655488</pmcid><pubmed_authors>Sun L</pubmed_authors><pubmed_authors>Moazzen S</pubmed_authors><pubmed_authors>He F</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Fan J</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Chen D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in Osteoarthritis Patients: Results from NHANES III and NHANES 2001-2018.</name><description>&lt;h4>Objectives&lt;/h4>The role of Vitamin D (VD) in calcium balance and bone health makes VD a vital factor in osteoarthritis (OA). Studies that have evaluated the effect of VD on OA patients have mainly been performed on a short-term basis. In this analysis, we aimed to evaluate whether VD was associated with mortality, a long-term outcome, in OA patients.&lt;h4>Methods&lt;/h4>Participants with self-reported OA from NHANES III and NHANES 2001-2018 were included. Associations of 25(OH)D concentrations with mortality risk were assessed continuously using restricted cubic splines and by categories (i.e., &amp;lt;25.0, 25.0-49.9, 50.0-74.9, and ≥75.0 nmol/L) using the Cox regression model. Sensitivity and stratified analyses were performed to evaluate the robustness of the results.&lt;h4>Results&lt;/h4>A total of 4570 patients were included, of which 1388 died by 31 December 2019. An L-shaped association was observed between 25(OH)D concentrations and all-cause mortality, whereas an inverse association was found for cardiovascular disease (CVD) mortality. The adjusted hazard ratios (95% confidence intervals) across four categories were 1.00 (reference), 0.49 (0.31, 0.75), 0.45 (0.29, 0.68), and 0.43 (0.27, 0.69) for all-cause mortality and 1.00 (reference), 0.28 (0.14, 0.59), 0.25 (0.12, 0.51), and 0.24 (0.11, 0.49) for CVD-specific mortality; no significant associations were found for cancer-specific mortality. Similar results were observed when stratified and sensitivity analyses were performed.&lt;h4>Conclusions&lt;/h4>Compared with patients with insufficient or deficient serum 25(OH)D, those with sufficient 25(OH)D concentrations had a lower risk of all-cause and CVD mortality, supporting a beneficial role of VD on a long-term basis.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-25T23:36:07.736Z</modification><creation>2025-04-06T09:23:21.374Z</creation></dates><accession>S-EPMC9655488</accession><cross_references><pubmed>36364891</pubmed><doi>10.3390/nu14214629</doi></cross_references></HashMap>